PARUTIONS DES ONCOLOGUES ET HEMATOLOGUES DU GHdC

Dr. Canon

Symann M, Rodhain J, Huybrechts M, Chatelain C, Humblet Y, Canon JL, Sokal G.  In vivostudies of a murine myeloblastic leukaemia.
Nouv. Rev. Franc. Hematol. 22 : 63-68, 1980.

Symann M, Huybrechts M, Chatelain C, Canon JL, Sokal G.
Regulation of granulocyte and macrophage formation studied in vivowith the diffusion chamber technique.
Nouv. Rev. Franc. Hematol. 22 : (supplement) 17-24, 1980.

Symann M, Anckaert MA, Huybrechts M, Ninane J, Canon JL, Sokal G.
In vivo stimulation and inhibition of granulopoiesis.   The effect of an inflammatory reaction on murine diffusion chamber granulopoiesis.
Brit J Haematol 1982 May; 51 (1) : 89 - 98.

Ninane J, Canon JL, Cornu G, Sokal G, Symann M.
Effect of lithium on diffusion chamber granulopoiesis.
Int J. Cell Clon 2 1984 Jul; 2 (4) : 216 - 226.

Symann M, Ninane J, Hamood M, Chatelain C, Canon JL, Sokal G.
In vivo stimulation and inhibition of granulopoiesis at the stem cell level.  Hematopoietic stem cell physiology.
Edt. Eugene P. Cronkite, Alan R. Liss, N.Y. 184 : 203-212, 1985.

Symann M, Humblet Y, Canon JL, Lebacq-Verheyden AM.
Detection of bone marrow metastases in small cell lung cancer by tumor stem cell assay and by monoclonal antibodies.
Dicke KA, Spitzer G, Yagannath S. Eds. : Autologous bone marrow transplantation.  Proceeding of the Third International Symposium.  Houtson, Texas : University of Texas M.D. Anderson Hospital and Tumor Inst. pg. 509-513, 1986.

Humblet Y, Canon JL, Sekhavat M, Feyens AM, Manouvriez P, Lebacq-Verheyden AM, Bazin H, Prignot J, Symann M.
Detection of small cell lung cancer bone marrow metatases by immunofluorescence.
Pathol.  Biol. 1988 Jan; 36 (1) : 25 - 28.

Canon JL, Humblet Y, Lebacq-Verheyden AM, Prignot J, Symann M.
Immunodetection of small cell lung cancer mestatasis in bone marrow  using three different monoclonal antibodies.
Eur J Cancer Clin Oncol. 1988 Feb; 24 (2) : 145 - 150.

Humblet Y, Feyens AM, Sekhavat M, Agaliotis D, Canon JL, Symann M.
Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts.
Cancer Res 1989 Sep 15 ; 49 (18) : 5058 - 5061.

Symann M, Humblet Y, Bosly A, Canon JL, Doyen C, Longueville J.
Intensification thérapeutique avec autogreffe de moelle osseuse chez l’adulte.
Path.  Biol. 1989 Nov; 37 (9) : 969 - 872 .

Canon JL, Humblet Y, Symann M.
Resistance to ciplastin : how to deal with the problem ?
Eur. J. Cancer 1990 Jan; 26 (1) : 1 – 3.  Review.

Weyants P, Humblet Y, Canon JL, Symann M.
Biology of small lung cancer : a overview.
Eur. Resp. J. 1990 Jun ; 3 (6) : 699 – 744.  Review.

Canon JL, Longueville J, Humblet Y, Symann M.
Critères de pronostic des cancers du sein sans envahissement des ganglions axillaires.
Louvain Méd. 109 : 667-674, 1990.

André M, Canon JL, Levecque P, Dermine P, Mortier C, Leveau F.
Eosinophilia-myalgia syndrome associated with L-tryptophan : a case with pulmonary manifestation and review of the litterature.
Acta Clinica Belgica 1991; 46 (3) : 178-182.  Review.

D’Hondt V, Weynants P, Humblet Y, Guillaume T, Canon JL, Beauduin M, Duprez P, Longueville J, Müll R, Chatelain C, Symann M.
Dose-dependant II-3 stimulation of thrombopoiesis and neutropoiesis in patients with small cell lung carcinoma before and following chemotherapy : a placebo controlled randomised phase Ib study.
2071 Clin. Oncol. 1993 Nov; 11 (11) : 2063 - 2071.

Hulstaert R, Van Belle S, Bleiberg H, Canon JL, Dewitte M, Buyse M, De Keyser P.
Optimal combination therapy with tropisetrom in 445 patients with subtotal control of chemotherapy-induced nausea and emesis.
2446 Clin. Oncol. 1994 Nov; 12 (11) : 2439 - 2446.

Van Belle S, Cocquyt V, Bleiberg H, Canon JL, Buyse M, Hustaert F, Dewitte M, De Keyser P, Westelinck K for the Belgian Novaban Group.
Optimal combination therapy with NovabanR(Tropisetron) in patients with incomplete control of Chemotherapy – induced Nausea and Vomiting.
Anti-Cancer Drugs 1995 Feb; 6 Suppl 1 : 22 - 30.

Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon JL, Laurent C, Naeyaert JM, Plagne R, Deraemaeker R, Knuth A, Jäger E, Brasseur F, Herman J, Coulie PJ, Boon T.
Tumor regression responses in melanoma patients treated with a peptide encoded by gene Mage 3.
Int. J. Cancer : 63, 883-885, 1995.

D’Hondt L, André M, Guillaume T, Emmons Van Dueren R, Feyens AM, Canon JL, Chatelain B, Humblet Y, Longueville J, Symann M.
The Administration of filgrastin (10µg/kg) alone results in successful peripheral with chemotherapy and hematopoïetic growth factor failed.
Leukemia and Lymphoma, 1998.  Vol 00 : p1-5

D’Hondt L, Andre M, Canon JL, Guillaume Th, Doyen Ch, Feyens AM, Chatelain B, Dromelet A, Humblet Y, Longueville J, Symann M.
Efficacité d’une chimiothérapie FEC à forte dose pour la mobilisation des cellules souches hématopoïétiques dans le sang périphérique.
Bull Cancer 1997 Jul; 84 (7) : 729 - 733.

Sibille-Hoang C, Froment O, Joos de ter Beest A, Lepiece V, Huberlant G, Blauwaert B, Vindevoghel A, Canon JL, Gillerot Y.
BRCA1/BRCA2 mutations in Belgian families with history of breast/ovary cancer.
Eur. J Cancer Prev. 1998 Feb; 7 Suppl 1 : S3 - 5.

Van de Velde H., Bosquée L., Neymants P., Canon JL., Rosier F., Humblet Y.
Moderate dose – escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small cell lung cancer : Prolonged intrathoracic tumor control anal high central nervous system relax rate. Groupe d’Oncologie-Pneumologie clinique de l’Université Cathologique de Louvain, Brussels and Liège, Belgium.
Am. Oncol 1999 Sep ; 10 (9) : 1051 - 1057

D’Hondt L, Emmons R, André M, Guillaume Th, Feyens AM, Canon JL, Humblet Y, Longueville J, Symann M
The Administration of 10 µg/dl Granylocyte Colony-Stimulating Factor (G-CSF) Alone Results in a Successful Peripheral Blood Stem Cell Collection When Previous Mobilization with Chemotherapy and Hematopoietic Growth Factor Failed.
Leukemia and Lymphoma, 1999 Jun; 34 (1 – 2) : 105 - 109.

Richel DJ, Johnsen HE, Canon JL, Guillaume Th, Schaafsma MR, Schenkeveld C, Hansen SW, McNiece I, Gringeri AJ, Briddell R, Ewen C, Davies R, Freeman J, Miltenyi S, Symann M.
Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients.
Bone Marrow Transplantation 25, p 243 – 249, 2000.

Focan C, Bury J, Beauduin M, Herman ML, Vindevoghel A, Lecomte M, Brohee D, Canon JL, Focan-Henrard D for the GRECCR Belgium.
Importance of 5-Fluorouracil Dose-Intensity in a Double Randomised Trial on Adjuvant Portal and Systemic Chemotherapy for Dukes B2 and C Colorectal Cancer
Anticancer Research 20 : 2000  Nov – Dec; 20 (GC) : 4665 - 4672

Andre M, Beaudoux E, Bron D, Canon JL, D’Hondt V, Fassotte MF, D’Hondt L, Fillet G, Humblet Y, Jerusalem G, Vermeulen P, Symann M, Beguin Y.
Phase III randomized study comparing5 or 10 microg per kg per day of filgrastin for mobilisation of peripheral blood progenitor cells with chemotherapy followed by intensification anal autologous. Transplantation in patients with non myeloid malignancies.
Transfusion 2003 Jan ; 43 (1) : 50 – 7

D’Hondt L, Andre M, Canon JL
Cyclin E. in breast cancer
NEJM 2003 mars 13; 348 (11) : 1063 – 4; author reply 1063 - 4

Belpomme D, Krabowki I., Beauduin M., Petit T., Canon JL.,  Janssens J., Gauthier  S., De Pauw A., Moreau V., Kayitalire L.
Gemcitabine combined with Cisplatin as first-line treatment in patients with epithelial ovarian cancer : a phase II, study
Gynecol Oncol 2003 octobre ; 91(1) : 32 – 8

S Henry, L D’hondt, M Andre, X Holemans, JL Canon
Saccharomyces cervisiae fungemia in a head and neck cancer patient: a case report and revieuw of the literature.
Acta Clinica Belgica, 2004: 59(4): 220-2

Focan C, Beauduin M, Majois F,Canon JL, Cusumano P, Focan-Henrard D, Labelle JP.   For the Adjuvant Breast Cancer Project, Belgium
High dose oral Medroxyprogesterone acetate or Tamoxifen as adjuvant hormonotherapy for node negative early breast cancer : randomized trial with 7 year update
Clinical Breast Cancer, 2004 Jun; 5 (2) : 136 – 141

Henry S, D’Hondt L, André M, Holemans X, Canon JL
Saccharomyces cerevisiae fungemia in a head and neck cancer patient : a case report and review of the literature
Acta Clin Belg. 2004 Jul-Aug ; 59 (4) : 220-2. Review

Focan C, Graas MP, Beauduin M,Canon JL, Salmon JP, Jerusalem G, Focan-Henrard D, Lobelle JP, Schallier D.
Sequential Administration of Epirubicin and Paclitaxel for Advanced Breast Cancer.
A phase I Randomised Trial Anicancer Research 2005 25(2B) : 1211-7

J Vansteenkiste, JL Canon, H Riska, R Pirker, P Peterson, W John P Mali, M Lahn;
Randomized phase 2 evaluation of aprinocarsen in combiation with gemcitabine and    cisplatin for patients with advanced/metastatic non-small cell lung cancer
Invest New Drugs 2005, 23(3): 263-269

JP Machiels, L Duck, B Honhon, B Coster, JC Coche, P Scalliet, Y Humblet, S   Aydin, J Kerger, V Remouchamps, JL Canon, P Van Maele, L Gilbeau, S Laurent
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cnacer: the RacOxCape study.
Ann Oncol. 2005, Dec; 16 (12): 1898 -1905

Canon JL, Vansteenkiste J, Bodoty G, Mateos MV, Bastit L.
Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa fort the treatment of chemotherapy induced anemia.
Natl Cancer Inst. 2006 Feb 15; 98 (4): 273 – 284

S Giacchetti, G Bjarnaso, C Garufi, D Genet, S Iacobelli, M Tampellini, R Smaaland,  C Focan, B Coudert, Y Humblet, JL Canon, A Adenis, G Lo Re, C Carvalho, J Schueller, N Anciaux, MA Lentz, B Baron, T Gorlia, F Levi on behalf the EORTC chronotherapy group
Phase 3 trial of 4-day chronomodulated vs 2-day conventional delivery of 5-fluorouracil, leucovorin and oxaliplatin as first line chemotherapy of metastatic colorectal cancer by the EORTC chronotherapy group
Clin Oncology 2006, Aug 1; 24 (22) : 3562 -3569

H Roché, P Fumoleau, M Spielmann, JL Canon, T Delozier, D Serin, M Symann, P Kerbrat, P Soulié, JP Brettes, P Viens, A Monnier, A Vindevoghel, C de Ghislain, MJ Goudier, J Bonneterre, JM Ferrero, H Orfeuvre, G Romieu, G Jerusalem, B Audhuy, M Campone, T Petit, G Piot, P Chollet, C Veryet, JC Eymard, AL Martin, J Genève, B Asselain
Sequential adjuvant chemotherapy with epirubicin and docetaxel for node-positive breast cancer patient
Clin. Oncol. 2006; Dec 20; 24 (32) : 5664 – 5671

D’Hondt L, Lonchay C, Andre M, Canon JL.
Oral Mucositis induced by anticancer treatments : physiopathology and treatment therapeutic and clinical risk management
The Clin Risk Management 2006 : 2 (2) : 159 – 168

Van Puijenbroeck R, Borsquée L, Meert AP, Schollier D, Goemine JC, Tits G, Collard P, Nachaert K, Canon JL, Duplaquet F, Galdermans D, Germanpre P, Azerad MA, Vandenhoven G, De Greve J, Vansteekiste G.
Gepinitib monothérapie in advanced non small all lung cancer : a large western community implementation study.
Eur. Resp. J. 2007 Jan ; 29 (1) : 128 – 133

R Giulani, V Durbecq, A Di Leo, M Paesmans, D Larsimont, JY Leroy, A    Vindevoghel, G Jerusalem, V D’hondt, L Dirix, JL Canon, V Richard, V Cocquyyt, F Majois, M Reginster, J Demol, JP Kains, P Delree, C Keppens, C Sotiriou, M Piccart, F Cardoso
Phosphorylated HER2 tyrosine Kinase and Her-2/neu gene amplification as   predictive factors of response to trastuzumab in patienst with HER-2 overexpressing metastatic breast cancer (MBC)
Eur. J. Cancer. 2007. Mar ; 43 (4) : 725 – 735

Machiels JP, Sempoux C, Scallet P, Coche JC, Humblet Y, Van Cutsem E, Kerger J, Canon JL, Peeters M, Agohin S, Laurent S, Kartheuser A, Coster B, Roels S, Daisne JF, Honhon B, Duch L, Kirkove C, Bonny MA, Haustermans V.
Phase I/II study of preoperative Cetuximab, Capecitabine and external beam Therapy in patients with rectal cancer.
Ann. Oncol. 2007, Apr; 18 (4) : 738 - 744

Van Cutsem E, Peeters M, Sience S, Humblet Y, Hendliz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richarson G, Wolf M, Amado R.
An open Label Randomized, Phase 3 clinical trial of Panitunimab plus best supportive care versus supportive car in patients with chemotherapy refractory metastatic colorectal cancer.
Clin. Oncol. 2007, May 1; 25 (13) : 1658 - 1664

D Kotasek, JL Canon, J San Miguel, M Hedenus, G Rossi, K Taylor
A randomized controlled trial comparing Darbepoetin alpha correction/maintenance dosing with weekly dosing fort treating chemotherapy induced anemia.
Current Medical Research and Opinion; 23; n°6; 2007; 1387 - 1401

Decelle L, D’Hondt L, Andre M, Calicis B, Lonchay C,Ide C, Canon JL
Ovarian Cancer associated with carcinomatory meningitis : a case report and review of the literature.
Int. J. Gynecol. Cancer 2007; 17 (5) : 1136 - 1140

Hubert C, Sempour S, Hermans Y, Mabier J, Hamblet Y, Machiels JP, Coratti A, Canon JL, Gigot JF.
Nodular regenerative hyperplasia : a deleterioux consequence of chemotherapy for colorectal liver metastases.
Liver Int 2007; 27 (7) 938 – 943

Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kosatach D, Santoro A, Scheithauer W, Spadajora S, Amaoto R, Hogan N, Peeter
An open-label, single arm study assessing safety and efficacy of panitunumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
Ann Oncol 2007 sep 4

Detrait M, D’Hondt L, André M, Lonchay C, Holemans X, Maton JP, Canon JL
Agrobacterium radiobacter bacterimia in oncology and geriatric patients : presentation of two cases and review ot the literature.
In J. Infect Dis. 2008 Nov; 12 (6): e7 – 10

Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, Di Bartolomeo M, Mazier MA, Canon JL, Geogoulias V, Peeters M, Bridgewater J, Cunnigham D, on behalf of the First BEAT investigaros.
Safety and Efficacy of fist-line bevacizumab with FOLFOX, XELOX, FOLFIRI and Fluoropyrimidines in metastatic colorectal cancer : The BEAT Study.
Ann Oncol. 2009, Nov. 20 (11) : 1842-7.

Van Vlaenderen I., Canon JL, Cocquyt V., Jausalen G., Machiels JP, Neven P. , Nechelput M., Delabaye I., Gyldmark M., Annemans L.
Trastuzumab Treatment of early stage, Breast Cancer is cost-effective from the perspective of the Belgian health care autorities.
Acta Clin Belg. 2009, Mar – Apr ; 64 (2) : 100 - 12

Spielmann M., Roché H., Delozier T., Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy AC, Fumoleau P, Maerevoet M, Piot G, Kramar A, Martin AL, Pénault-Llorca F.
Trastuzumab for patients with axillary-node positive breast cancer : results of the FNCLCC-PACS 04 trial.
JCO, 2009 Dec 20 ; 27 (36) : 6129-34. 

Verbeke N., Bosly A., Wildiers H., Canon JL, Bries G, Beguin Y, Van Belle S.
High prevalence of anaemia and limited use of therapy in cancer patients : a Belgian survey (Anaemia Day 2008).
Support Care Cancer, 2010 Nov 25.

Douillard JY, Siena S, Cassidy J, Tabernera J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner Kelly S., Wolf M, Gansert J.
Randomized, Phase 3 Study (Prime) of Panitumumab with Folfox 4 versus Folfox 4 Alone as First-line Treatment in Patients with Previously Untreated Metastatic Colorectal Cancer.
J Clin Oncol. 2010 Nov 1 ; 28 (31) : 4697-705. Epub 2010 Oct. 4.

Vanderhofstadt M., D’hondt L, André M., Lonchay C., Levecque P., Holemans X., Canon JL
Clostridium tertium bacteriema : contamination or true pathogen ? A report of two cases and a review of the literature
International Journal of Infectious Diseases, 2010 Sep; 14 Suppl 3:e335-7.

Wildiers H, Fontaine C, Vuylsteke P, Martens M, Canon JL, Wynendaele W, Focan C, De Greve J, Squifflet P, Paridaens R.
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.
Breast Cancer Res Treat. 2010 Sep ; 123 (2) : 463-9.

Dirix L., Awada A., Bron D., Canon JL, De Grève J., Humblet Y., Peeters M., Van Belle S., Vansteenkiste J., Vermorken J.
Practice guidelines on the use of erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia.
Belgian Journal of Medical Oncology, volume 4, issue 2, 2010

Janus N., Launay-Vacher V., Byloos E., Machiels JP, Duck L., Kerger J., Wynendaele W., Canon JL, Lybaert W., Nortier J., Deray G, Wildiers H. 
Cancer and renal insufficiency results of the BIRMA study.
Br J Cancer, 2010 Dec.7;103(12):1815-1821.

Verbeke N, Beguin Y, Wildiers H, Canon JL, Bries G, Bosly A, Van Belle S.
High prevalence of anaemia and limited use of therapy in cancer patients : a Belgian survey (Anaemia Day 2008)
Support Care Cancer. 2012 Jan ; 20 (1) : 23-8

Rayson D, Suter TM, Jackisch C, van der Vegt S, Bermejo B, van den Bosch J, Vivanco GL, van Gent AM, Wildiers H, Torres A, Provencher L, Temizkan M, Chirgwin J, Canon JL, Ferrandina G, Srinivasan S, Zhang L, Richel DJ
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab : a randomized phase II trial
Ann Oncol. 2012 Jul ; 23 (7) : 1780-8

Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Pénault-Llorca F, Serin D, Lévy C, Romieu G, Canon JL, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard JC, Roché H ; UNICANCER Breast Group
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer : the 8-year follow-up results of the UNICANCER-PACS01 trial.
Oncologist. 2012 ; 17 (7) : 900-9. doi : 10. 1634/theoncologist.2011-0442

Roy A, Cunningham D, Hawkins R, Sörbye H, Adenis A, Barcelo JR, Lopez-Vivanco G, Adler G, Canon JL, Lofts F, Castanon C, Fonseca E, Rixe O, Aparicio J, Cassinello J, Nicolson M, Mousseau M, Schalhorn A, D’Hondt L, Kerger J, Hossfeld DK, Garcia Giron C, Rodriguez R, Schoffski P, Misset JL.
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer : a randomised phase II study.
Br J Cancer. 2012 Jul 24 ; 107 (3) : 435-41.

Mardjuadi F, Medioni J, Kerger J, D’hondt L, Canon JL, Duck L, Musuamba F, Oudard S, Clausse M, Moxhon A, Machiels JP.
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Cancer Chemother Pharmacol. 2012 Aug ; 70 (2) : 293-303.

Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart M, Harbeck N.
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.
Breast Cancer Res Treat. 2012 Aug ; 134 (3) : 1149-59.

Canon JL, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K.
Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline haemoglobin level of <9 g/dl versus 9 to <10 g/dl versus ≥ 10 g/dl : an exploratory analysis of a phase 3 trial.
Med Oncol. 2012 Sep ; 29(3) : 2291-9. doi : 10.1007/s12032-011-0103-x. Epub 2011 Nov 13.

Seront E, Rottey S, Sautois B, Kerger J, D’Hondt L.A, MD, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP
Phase II study of Everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract : clinical activity, molecular response and biomarkers.
Ann Oncol. 2012 Oct ; 23 (10) : 2663-70.

Cardoso F, Canon JL, Amadori D, Aldrighetti D, Machiels JP, Bouko Y, Verkh L, Usari T, Kern KA, Giorgetti C, Dirix L.
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Breast. 2012 Dec ; 21 (6) : 716-23.

Roca L, Diéras V, Roché H, Lappartient E, Kerbrat P, Cany L, Chieze S, Canon JL, Spielmann M, Penault-Llorca F, Martin AL, Mesleard C, Lemonnier J, de Cremoux P.
Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial Breast Cancer Res Treat. 2013 Jun, 139(3) : 789-800.  doi  : 10.1007/s10549-013-2587-x Epub 2013 Jun 19.

Forget P, Machiels JP, Coulie PG, Berliere M, Poncelet AJ, Tombal B, Stainier A, Legrand C, Canon JL, Kremer Y, De Kock M.
Neutrophil : Lymocyte Ratio and Intraoperative Use ok Ketorolac or Diclofenac are Prognostic factors in Different Cohorts of Patients Undergoing Breast, Lung, and Kidney Cancer Surgery
Ann Surg Oncol. 2013 Jul 25.

Filleron T, Md FD, Kramar A, Spielmann M, Levy C, Fumoleau P, Canon JL, Martin AL, Roché H.
Prognostic factors of young women (<35 years) with node positive breast cancer : possible influence on post-therapeutic follow-up
Bull Cancer. 2013 Jul 3.

Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delree P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart M, Sotiriou C.
Genomic Grade Index (GCI) : Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer
PLoS One. 2013 Aug 19;8(8):e66848.doi:10.1371/journal.pone.0066848.
PMID:23990869 (PubMed – in process)

Schwartzeberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go Wy.
PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresecable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
J Clin Oncol. 2014 Apr 21. (Epub ahead of print)
PMID:24687833 (PubMed – as supplied by publisher)

Elalamy I, Canon JL, Bois A, Lybaert W, Duck L, Jochmans K, Bosquee L, Peeters M, Awada AH, Clement P, Holbrechts S, Baurain JF, Mebis J, Nortier J.
Thrombo-Embolic Events in Cancer Patients with impaired Renal Function.
Blood disorders Transf 2014: 5.4

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Tian Y,  Xu F, Sidhu R.
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Ann Oncol. 2014 Jul; 25(7): 1346-55.doi: 10.1093/annonc/mdu141. Epub 2014 Apr 8.
PMID:24718886 (PubMed – in process)

Toffoli S, Bar I, Abdel-Sater F, Delrée P, Hilbert P, Cavallin F, Moreau F, Van Criekinge W, Lacroix-Triki M, Campone M, Martin AL, Roché H, Machiels JP, Canon JL.
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Breast Cancer Res. 2014 Nov 22; 16(6):466

Feby Ingriani Madjuadi, Javier Carrasco, Jean-Charles Coche, Christine Sempoux, Anne Jouret-Mourin, Pierre Scalliet, Jean-Charles Goeminne, Jean-François Daisne, Thierry Delaunoit, Peter Vuylsteke, Yves Humblet, Nicolas Meert, Marc, Van den Eyden, Anne Moxhon, Karin Haustermans, Jean-Luc Canon,Jean-Pascal Machiels.
Panitumumab as a radiosensitizing agent in KRASwild-type locally advanced rectal cancer.
Target Oncol. 2015 Sep;10(3):375-83. Doi: 10.1007/s11523-014-0342-9. Epub 2014 Oct 11.

De Grève J, Moran T, Graas MP, Galdermans D, Vuylsteke P, Canon JL, Schallier D, Decoster L, Teugels E, Massey D, Chand VK, Vansteenkiste J.
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
Lung Cancer. 2015 Apr ;88(1) :63-9. doi:10.1016/j.lungcan.2015.01.013.Epub 2015 Jan23
Lung Cancer. 2015 Apr;88(1):63-9. doi: 10.1016/j.lungcan.2015.01.013. Epub 2015

Vansteenkiste JF, Canon JL, Braud FD, Grossi F, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli C, Dy GK, Thongprasert S, Reck M, Aimone P, Vidam GA, Roussou P, Wang YA, Di Tomaso E, Soria JC.
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer : Résults from the Phase II BASALT-1 Study.
J Thorac Oncol. 2015 Sep;10(9): 1319-27.doi: 10.1097/JTO.0000000000000607.
PMID:26098748

De Grève J, Van Meerbeeck J, Vansteenkiste JF, Decoster L, Meert AP, Vuylsteke P, Focan Canon JL, Humblet Y, Berchem G, Colinet B, Galdermans D, Bosquée L, Vermeij J, Dewaele A, Geers C, Schallier D, Teugels E.
Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)
PLoS One. 2016 Mar 31;11(3):e0147599. doi: 10.1371/journal.pone.0147599. eCollection 2016.
PMID: 27032107 Free Article

Limentani SA, Campone M, Dorval T, Curigliano G, de Boer R, Vogel C, White S, Bachelot T, Canon JL, Dissi M, Awada A, Berlière M, Amant F, Levine E, Burny W, Callegaro A , de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF.
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic fort the treatment of breast cancer patients with HER2-overexpressing tumors.
Breast Cancer Res Treat. 2016 Apr;156(2):319-30. doi: 10.1007/s10549-016-3751-x. Epub 2016 Mar 18.
PMID: 26993131

Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL,Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF.
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.
Breast Cancer Rest Treat. 2016 Apr;156(2):301-10. doi: 10.1007/s105749-016-3750-y. Epub 2016 Mar 14.
PMID: 26975198

Dr Carrasco 

Godelaine D., Carrasco J., Lucas S., Karanikas V., Schuler-Thurner B., Coulie P., Schuler G., Boon T., and Van Pel A. Polyclonal cytolytic T
lymphocyte responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. Journal of
Immunology, 171:4893-4897, 2003.

Zhang Y., Sun Z., Nicolay H., Meyer R., Renkvist N., Stroobant V.,Corthals K., Carrasco J., Eggermont A., Marchand M., Thielemans K., Wölfel T., Boon T., and van der Bruggen P.
Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.
The Journal of Immunology, 174 : 2404-2411, 2005.

Carrasco J., Godelaine D., Van Pel A., Boon Th., Van der Bruggen P.
CD45RA on human memory CD8 T cells is a marker for the time elapsed since the last antigenic stimulation.
Blood, 108 2897-2905 ; 2006

Godelaine D., Carrasco J., Brasseur F., Neyns B., Thielemans K., Boon Th., and Van Pel A.
A new tumor-specific antigen encoded by MAGEC2 and presented to cytolytic T lymphocytes by HLA-B44. Cancer
Immunol Immunother ; 56(6) : 753-9; 2007

Carrasco J, Van Pel A, Neyns B, Lethé B, Brasseur F, Renkvist N, van der Bruggen P, van Baren N, Paulus R, Thielemans K, Boon T, Godelaine D.
Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells.
The Journal of Immunology, Mar 1; 180(5) : 3585-93, 2008.

Demotte N, Wieërs G, Van Der Smissen P, Moser M, Schmidt C, Thielemans K, Squifflet JL, Weynand B, Carrasco J, Lurquin C, Courtoy PJ, van der Bruggen P.
A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice.
Cancer Res. 2010 Oct 1;70(19):7476-88. Epub 2010 Aug 18

Godelaine D., Carrasco J., Thielemans K., Boon T., and Van Pel A.
Contrasting frequencies of anti-tumor and anti-vaccine T cells in a patient vaccinated with peptide-pulsed dendritic cells. 8th International
Symposium on Dendritic Cells, Brugge, Belgium, October 17-21, 2004.

Carrasco J., Van Pel A., Godelaine D., and Boon T.
Transient reexpression of CCR7 after antigenic contact characterizes high expanding CTL. Poster presentation.
8th International Symposium on Dendritic Cells, Brugge, Belgium, October 17-21, 2004.

Carrasco J., Feyens AM., Gillain A., Machiels JP., Hammouch F., Coulie PG. and Baurain J-Fr., Immunization of melanoma patients at high risk of relapse.
Oral presentation on BSMO symposium. February 4 2006

Van den Eynde, M. Gizzi, G. Pairet, P. Lefevre, V. Lannoy, JF. Gigot, C. Hubert, B. Navez, N. Tinton, Y. Humblet, JL. Canon, A. Mourin, Ch. Sempoux and J. Carrasco.
Comparison of pathological responses (PR) observed on colorectal cancer metastases (CRCM) resected after different preoperative treatments.
ESMO 2012

Theo JM Ruers, Daniela Aust, Marc Van den Eynde, Gunnar Folprecht,Javier Carrasco, Martin Fuchs, Jitske Martha Smit, Anja Victors and Sonia Quaratino, Randomized, open-label study of the biological effects of BLP25 liposome (L-BLP25) immunotherapy in rectal cancer patients undergoing neoadjuvant chemoradiotherapy: SPRINT study design.
ESMO 2012

Dr Gizzi

Another case of "European hantavirus pulmonary syndrome" with severe lung, prior to kidney, involvement, and diagnosed by viral inclusions in lung macrophages.
Gizzi M, Delaere B, Weynand B, Clement J, Maes P, Vergote V, Laenen L, Hjelle B, Verroken A, Dive A, Michaux I, Evrard P, Creytens D, Bulpa P.
Eur J Clin Microbiol Infect Dis. 2013 May 14.

Tubulocystic carcinoma of the kidney with fatal outcome in an adolescent male.
Gizzi M, Aydin S, Machiels JP.
Urologia Internationalis 2014 Dec 16. (Epub ahead of print). PMID: 25531760

Novel membrane based targets-Therapeutic potential in gynecological cancers.
Gizzi M, Pautier P, Lhomme C, Leary A.
Critical review in Oncology & Hematology. 2014 Nov 18. (Epub ahead of print) Review. PMID 25523485.

La gynécologie à l’ASCO 2014.
Gizzi M, Leary A.
Réfléxions en Médecine Oncologique.Septembre 2014

PUBLICATIONS AS CO-AUTHOR

Axitinib in renal cell carcinoma.
Albigès L, Gizzi M, Escudier B.
Expert review of anticancer therapy. 2015. Article in Press.

« Late recurrent testicular seminoma: histologic evidence required ».
Lebacle C, Gizzi M, Lambotte O, Ackermann F, Lazure T, Michot JM, Massard C.
Oncology research and treatment. 2015. 2015;38(6):286-8. doi: 10.1159/000430794. Epub 2015 May 19. 

Carcinomes urothéliaux, formes métastatiques : traitements médicaux d’aujourd’hui et de demain. Lavaud P, Gizzi M, Loriot Y.
Oncologie. Avril 2015. ; 17(4):178-183. DOI: 10.1007/s10269-015-2505-4

Pathological responses after angiogenesis inhibitors or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone. Carrasco J, Gizzi M, Pairet G, Lannoy V, Lefesvre P, Gigot JF, Hubert C, Jouret-Mourin A, Humblet Y, Canon JL, Sempoux C, Chapaux X, Danse E, Tinton N, Navez B, Van den Eynde M.
Br J Cancer. 2015 Nov 3;113(9):1298-304. doi:10.1038/bjc.2015.321. Epub 2015 Oct 13.

POSTER SESSIONS

Comparison of pathological responses observed on colorectal cancer metastases (CRCM) resected after different preoperative treatments.
M. Van den Eynde, M Gizzi, G Pairet, P Lefevre, V Lannoy, JF Gigot, B Navez, JL Canon, Ch Sempoux and J Carrasco.
2012 European Society for Medical Oncologist (ESMO) meeting, Vienna, Austria.

Early PSA response is an independent prognostic factor in patients with mCRPC treated with next-generation androgen pathway inhibitors.
A Fuerea, G Baciarello, C Massard, L Albiges, M Gizzi, S Terrisse, M Di Palma, B Escudier, K Fizazi, Y Loriot.
2014 ESMO meeting, Madrid, Spain.

Previous enzalutamide therapy and response to subsequent taxane therapy in metastatic castration resistant prostate cancer.
M Gizzi, G Baciarello, P Beuzeboc, A Angelergues, G Roubaud, E Bompas, B Duclos, I Latorzeff, A Flechon,  Priou F, E Voog, R Delva, M Gross Goupil, C Vassal, A Patrikidou, K Fizazi, Y Loriot
Poster session. 2015 ASCO GU meeting, Orlando, USA.

Dr Honhon

Etude de la toxicité du CisDDP en chimiothérapie ambulatoire – a faible, moyenne et haute dose. Présentation orale au Séminaire d’Hématologie ( Namur 1983 – Prof. A. BOSLY)

Aspects récents de l’analyse moléculaire génétique de néoplasmes lymphoïdes B chez l’homme. Bulletin de la Société des Sciences Médicales du Grand-Duché de Luxembourg n°1, 1986,123°année –( B.Honhon, M. Dicato)

Dialysis amyloidosis .Advances in Nephrology, vol 17, 1988 - (Ch. Van Ypersele de Strihou, B.Honhon, J.M. Vandenbroucke, J.P. Huaux, H.Noel, B.Maldague)

Cholesterol embolism in a renal graft after treatment with streptokinase.British medical Journal, Feb 1988, 296, 394-395 ( Y. Pirson, B. Honhon, J.P. Cosyns, Ch. Van Ypersele de Strihou.

Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.Annals of Oncology  2007Jan ;5 (J.P. Machiels, C. Sempoux, P. Scalliet, J.-C. Coche, Y. Humblet, E. Van Cutsem, J. Kerger, J.-L. Canon, M. Peeters, S. Aydin, S.Laurent, A. Kartheuser, B. Coster, S. Roels, J.-F. Daisne, B. Honhon, L. Duck, C. Kirkove, M.-A. Bonny & K. Haustermans)

Phase ii  study of preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma : the radiOxcape study : annals of oncology 2005,16 : 1898-1905 -

Phase II study of preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma : the radiOxcape study. ASCO 2007 - Abstr No 245

Phase iii trial of docetaxel (d), estramustine (e), and prednisone versus docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer (hrpc) ; asco 2007 – abstr No 5067

Black pigments in the liver related to gold and titanium deposits.a report of 4 cases.R.Brenard, P. Dumortier, M. Del Natale , B. Honhon , M. Van den Berghe, C. Bataille, F. Rickaert, J. Henrion, MO. Peny, J. Rahier. (Liver international 2007Apr ;27(3))

Phase II study of weekly paclitaxel /carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers :A study in 108 patients by the Belgian Gynaecological Oncoly Group. Gynecologic Oncology 138(2015)278-284 (Ignace Vergote,Philip Debruyne,Frédéric Kridelka,Parick Berteloot,Frédéric Armant,Brigitte Honhon,Willem Lybaert,Karin Leunen,Kurt Geldhof,Didier Verhoeven,Frédéric Forget,Peter Vuylsteke,Lionel D’Hondt,Manon Huizing,Heidi Van den Bulk,Annouschka Laenen).

Dr Lonchay

Pierre G Coulie, Vaios Karanikas, Christophe Lurquin, Didier Colau, Thierry Conerotte, Takeshi Hanagiri, Aline Van Pel, Sophie Lucas, Danièle Godelaine, Christophe Lonchay, Marie Marchand, Nicolas van Baren, Thierry Boon.
Cytolytic T cell responses of cancer patients vaccinated with a MAGE antigen.
Immunological Reviews.  May 13, 2002.

Tetsuto Kobayashi, Christophe Lonchay, Didier Colau, Nathalie Demotte, Thierry Boon, Pierre van der Bruggen.
New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells.
Tissue Antigens. 2003 Nov.

Lonchay C, van der Bruggen P, Connerote T, Hanagiri T, Coulie P, Colau D, Lucas S,  Van Pel A, Thielemans K, van Baren N, Boon T.
Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.
Proc Natl Acad Sci U S A. Oct 5, 2004;101 Suppl 2:14631-8. Epub Sep 27, 2004.

Joncker NT, Marloie  MA, Chernysheva A, Lonchay C, Cuff S, Klijanienko J, Sigal-Zafrani B, Vincent-Salomon A, Sastre X, Lantz O.
Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors.
International Journal of Cancer. March 1, 2006.

D’Hondt Lionel, Lonchay Christophe, André Marc, Canon Jean-Luc
Oral mucositis induced by anticancer treatments: physiopathology and treatments.
Therapeutics and Clinical Risk Management. 2006:2.

Dr Sinapi

Sinapi I, Hammer F, Hainaut P.
Aortic mural thrombi associated with ulcerative colitis.
Acta Clin Belg

Sinapi I, Caers J, Connerotte T, Koutaissoff S, Lambert M.
Retroperitoneal fibrosis and multiple myeloma: fortuitous association?
Rev Med Interne

Un unusual case of haemolysis after lung transplantation: the passenger lymphocyte syndrome
Abstract et poster présenté  au symposium annuel de la Société  Belge de Pneumologie

M de Vos· P Druez· M Nicaise· P Ngendahayo· I Sinapi · P Mineur
Multiple myeloma presenting as hepatic nodular lesion
Acta clinica Belgica 11/2012; 67(5):378-80. DOI:10.2143/ACB.67.5.2062696

I Sinapi, B. Navez, M. Hamoir, S. Schmitz, JP Machiels , P. H Deprez, M. Van den Eynde
Head Neck. 2012 Jun 19. doi: 10.1002/hed.23015.
Seeding of the percutaneous endoscopic gastrostomy site from head and neck carcinoma: a case report and review of the literature. 

A.Rahal, V.Boige, D.Malka, C.Rahal, P.Burtin, I.Sinapi, D.Elias, D.Goere, B.Lacas, M.Ducreux.
Modified FOLFIRI (mFOLFIRI) as second line chemotherapy in advanced gastric cancer (AGC).
Abstract et poster : ESMO 14th World Congress on Gastrointestinal Cancer

Anna Patrikidou· Isabelle Sinapi · Hélène Regnault· Florence Fayard· Mohamed Bouattour· Laetitia Fartoux· Sandrine Faivre· David Malka· Michel Ducreux· Valerie Boige
Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies
Investigational New Drugs 04/2014; 32(5). DOI:10.1007/s10637-014-0100-y

Veereman· J. Robays· L. Verleye· R. Leroy· C. Rolfo· E. Van Cutsem· D. Bielen· W. Ceelen· E. Danse· M. De Man· P. Demetter· P. Flamen· A. Hendlisz· I. Sinapi · D. Vanbeckevoort· D. Ysebaert· M. Peeters·
Pooled analysis of the surgical treatment for colorectal cancer liver metastases
Critical Reviews in Oncology/Hematology 01/2015; 94(1). DOI:10.1016/j.critrevonc.2014.12.004·

Dr Verschaeve

Article: Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: Clinical activity, molecular response, and biomarkers
E Seront· S Rottey· B Sautois· J Kerger· L A D'Hondt· V Verschaeve · J-L Canon· C Dopchie· J M Vandenbulcke· N Whenham· J C Goeminne· M Clausse· D Verhoeven· P Glorieux· S Branders· P Dupont· J Schoonjans· O Feron· J-P Machiels·
Annals of Oncology 04/2012; 23(10):2663-70. DOI:10.1093/annonc/mds057 · 7.04 Impact Factor

Article: O10.07 * RANDOMIZED PHASE II STUDY OF AXITINIB VS. STANDARD OF CARE IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Duerinck· S. Du Four· F. Bouttens· V. Verschaeve · H. Everaert· S. De Raedt· A. Van Binst· B. Neyns
Neuro-Oncology 09/2014; 16(suppl 2):ii24-ii25. DOI:10.1093/neuonc/nou174.88 · 5.56 Impact Factor

Article: Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma
Johnny Duerinck· Paul M. Clement· Frank Bouttens· Chantal Andre· Bart Neyns· Yves Staelens· Frank Van Fraeyenhove· Jean-Francois Baurain· Sylvie Luce· Lionel D’hondt· Eric Joosens· Pol Specenier· Vincent Verschaeve · Bertrand Filleul· Philippe Vroman· Barbara Stragier· Anne Rogiers
Journal of Neurology 01/2015; 262(3). DOI:10.1007/s00415-014-7633-z · 3.38 Impact Factor

Article: A Belgian survey on geriatric assessment in oncology focusing on large-scale implementation and related barriers and facilitators
Kenis· P. Heeren· L. Decoster· K. Van Puyvelde· G. Conings· F. Cornelis· P. Cornette· R. Moor· S. Luce· Y. Libert· [...] · J.-P. Praet· C. Focan· V. Verschaeve · N. Nols· J.-C. Goeminne· B. Petit· J.-P. Lobelle· J. Flamaing· K. Milisen· Hans Wildiers
The Journal of Nutrition Health and Aging 05/2015; DOI:10.1007/s12603-015-0538-4 · 3.00 Impact Factor

Article: 8744 POSTER Extended Use of Adjuvant TMZ in Newly Diagnosed GBM Patients is Safe – Results From the Safety Analysis of the PATSGO Trial
Hammouch· T. Boterberg· P. Clement· E. Joosens· N. Whenham· V. Verschaeve · D. Devriendt· L. Renard· J. F. R. Baurain
European Journal of Cancer 09/2011; 47. DOI:10.1016/S0959-8049(11)72295-X · 5.42 Impact Factor

Article: Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer
Jean-Pascal Machiels· Filomena Mazzeo· Marylene Clausse· Bertrand Filleul· Luc Marcelis· Brigitte Honhon· Lionel D'Hondt· Catherine Dopchie· Vincent Verschaeve · Lionel Duck· Didier Verhoeven· Peter Jousten· Marie-Alix Bonny· Anne-Marie Moxhon· Bertrand Tombal· Joseph Kerger
Journal of Clinical Oncology 10/2008; 26(32):5261-8. DOI:10.1200/JCO.2008.16.9524 · 18.43 Impact Factor